Prespecified exploratory analyses on clinical endpoints demonstrated a reduced incidence of HF and reduced HF hospitalizations, supporting the potential clinical benefit of IL-1 blockade in patients with acute myocardial infarction [29]. Here, IL1A is linked to myocardial infarction.